-

08:55:19 AM

XRTX Stock News

XRTX - XORTX Therapeutics Inc

08/04/22 7:00 AM

Nasdaq : XRTX

clinical triallow float

XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat

RHEA-AI

very positive

07/22/22 8:00 AM

Nasdaq : XRTX

low float

XORTX Reports Annual & Special Meeting Results

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce

RHEA-AI

neutral

07/19/22 7:00 AM

Nasdaq : XRTX

low float

XORTX Announces Submission to European Medicines Agency

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on

RHEA-AI

positive

07/13/22 7:00 AM

Nasdaq : XRTX

clinical triallow float

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies

RHEA-AI

positive

07/07/22 7:00 AM

Nasdaq : XRTX

clinical triallow float

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce

RHEA-AI

positive

06/21/22 7:00 AM

Nasdaq : XRTX

low float

XORTX Announces “Fireside Chat” with XORTX CEO

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce

RHEA-AI

neutral

06/13/22 8:54 AM

Nasdaq : XRTX

conferenceslow float

XORTX to Present at BIO International Convention 2022

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce

RHEA-AI

neutral

06/08/22 7:00 AM

Nasdaq : XRTX

conferenceslow float

XORTX to Present at LD Micro Invitational 2022

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce

RHEA-AI

neutral

06/06/22 7:00 AM

Nasdaq : XRTX

managementlow float

XORTX Welcomes New Member to the Board of Directors and Appoints Chair

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to welcome

RHEA-AI

very positive

05/25/22 8:00 AM

Nasdaq : XRTX

conferenceslow float

XORTX to Present at H. C. Wainwright Global Investment Conference 2022

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its

RHEA-AI

neutral

XRTX Data

IndustrySupport Activities for Nonmetallic Minerals (except Fuels) Mining
Websitewww.xortx.com
CeoAllen Davidoff
Security nameXORTX Therapeutics Inc
Issue typecs
SectorMining, Quarrying, and Oil and Gas Extraction
Employees2021
AddressSuite 4000, 421 - 7th Avenue SW
StateAlberta
CityCalgary
ZipT2P 4K9
CountryCanada
Phone14036072621

About XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX Therapeutics is dedicated to developing medications to improve the quality of life and future health of patients.